🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
50.78
-0.68 (-1.32%)
At close: Nov 20, 2026, 4:00 PM EST
52.48
+1.70 (3.35%)
After-hours: Nov 20, 2026, 7:38 PM EST

Company Description

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.

The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.

It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction.

In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials.

Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics, Incorporated
Cytokinetics logo
CountryUnited States
Founded1997
IPO DateApr 29, 2004
IndustryBiotechnology
SectorHealthcare
Employees673
CEORobert Blum

Contact Details

Address:
350 Oyster Point Boulevard
South San Francisco, California 94080
United States
Phone650 624 3000
Websitecytokinetics.com

Stock Details

Ticker SymbolCYTK
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001061983
CUSIP Number23282W605
ISIN NumberUS23282W6057
Employer ID94-3291317
SIC Code2834

Key Executives

NamePosition
Robert I. BlumChief Executive Officer, President and Director
Sung H. LeeExecutive Vice President and Chief Financial Officer
Jeffrey J. Hessekiel J.D.Executive Vice President, Chief Legal and Administrative Officer
Dr. Fady Ibraham Malik FACC, M.D., Ph.D.Executive Vice President of Research and Development
Andrew M. CallosExecutive Vice President and Chief Commercial Officer
Dr. James H. Sabry M.D., Ph.D.Co-Founder and Chairman of Scientific Advisory Board
Dr. James A. Spudich Ph.D.Co-Founder and Member of Scientific Advisory Board
Holly LaughlinVice President of Accounting and Corporate Controller
Steven M. Cook J.D.Senior Vice President of Global Supply Chain Operations and Technical Operations
Scott R. JordanSenior Vice President of Global Marketing and Commercial Strategy

Latest SEC Filings

DateTypeTitle
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 10, 2026SCHEDULE 13GFiling
Nov 9, 2026144Filing
Nov 4, 202610-QQuarterly Report
Nov 4, 20268-KCurrent Report
Oct 20, 2026144Filing
Oct 13, 2026144Filing
Sep 15, 2026144Filing
Sep 11, 2026144Filing
Sep 1, 2026144Filing
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides